Community pharmacistephysician collaborative streptococcal pharyngitis management program

Donald G. Klepser, Michael E. Klepser, Allison M. Dering-Anderson, Jacqueline A. Morse, Jaclyn K. Smith, Stephanie A. Klepser

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objectives: To describe patient outcomes associated with a community pharmacyebased, collaborative physician-pharmacist group A Streptococcus (GAS) management program. Setting: Fifty-five chain and independent community pharmacies in Michigan, Minnesota, and Nebraska. Practice innovation: Pharmacists screened clinically stable adult patients who presented with signs and symptoms consistent with GAS pharyngitis from October 1, 2013, to August 1, 2014, by means of Centor criteria, and performed a physical assessment followed by a rapid antigen detection test (RADT) for eligible patients. Patients were treated according to a collaborative practice agreement (CPA) with a licensed prescriber or a physician consult site model. Pharmacists followed up with patients 24e48 hours after the encounter to assess patient status and possible need for further intervention. Evaluation: Number of patients screened, tested, and treated, and health care utilization. Results: Of 316 patients screened, 43 (13.6%) were excluded and referred for care. Of 273 patients (86.4%) eligible for testing, 48 (17.6%) had positive test results and 46 (16.8%) received amoxicillin or azithromycin per the CPA. Of those tested, 43.2% had no primary provider and 43.9% visited the pharmacy outside of traditional clinic office hours. Conclusion: Pharmacists demonstrated the ability and capacity to provide care for patients seeking treatment for pharyngitis. The number of patients without a primary care provider and seen at the pharmacy outside of normal office hours highlights the improved access that community pharmacyebased care offers.

Original languageEnglish (US)
Pages (from-to)323-329.e1
JournalJournal of the American Pharmacists Association
Volume56
Issue number3
DOIs
StatePublished - May 1 2016

Fingerprint

Patient treatment
Azithromycin
Pharyngitis
Amoxicillin
Health care
Innovation
Antigens
Testing
Pharmacists
Streptococcus
Patient Acceptance of Health Care
Physicians
Pharmacies
Signs and Symptoms
Primary Health Care
Patient Care

ASJC Scopus subject areas

  • Pharmacology (nursing)
  • Pharmacy
  • Pharmacology

Cite this

Community pharmacistephysician collaborative streptococcal pharyngitis management program. / Klepser, Donald G.; Klepser, Michael E.; Dering-Anderson, Allison M.; Morse, Jacqueline A.; Smith, Jaclyn K.; Klepser, Stephanie A.

In: Journal of the American Pharmacists Association, Vol. 56, No. 3, 01.05.2016, p. 323-329.e1.

Research output: Contribution to journalArticle

Klepser, Donald G. ; Klepser, Michael E. ; Dering-Anderson, Allison M. ; Morse, Jacqueline A. ; Smith, Jaclyn K. ; Klepser, Stephanie A. / Community pharmacistephysician collaborative streptococcal pharyngitis management program. In: Journal of the American Pharmacists Association. 2016 ; Vol. 56, No. 3. pp. 323-329.e1.
@article{542cadbc47aa46a697578180ccfeeddd,
title = "Community pharmacistephysician collaborative streptococcal pharyngitis management program",
abstract = "Objectives: To describe patient outcomes associated with a community pharmacyebased, collaborative physician-pharmacist group A Streptococcus (GAS) management program. Setting: Fifty-five chain and independent community pharmacies in Michigan, Minnesota, and Nebraska. Practice innovation: Pharmacists screened clinically stable adult patients who presented with signs and symptoms consistent with GAS pharyngitis from October 1, 2013, to August 1, 2014, by means of Centor criteria, and performed a physical assessment followed by a rapid antigen detection test (RADT) for eligible patients. Patients were treated according to a collaborative practice agreement (CPA) with a licensed prescriber or a physician consult site model. Pharmacists followed up with patients 24e48 hours after the encounter to assess patient status and possible need for further intervention. Evaluation: Number of patients screened, tested, and treated, and health care utilization. Results: Of 316 patients screened, 43 (13.6{\%}) were excluded and referred for care. Of 273 patients (86.4{\%}) eligible for testing, 48 (17.6{\%}) had positive test results and 46 (16.8{\%}) received amoxicillin or azithromycin per the CPA. Of those tested, 43.2{\%} had no primary provider and 43.9{\%} visited the pharmacy outside of traditional clinic office hours. Conclusion: Pharmacists demonstrated the ability and capacity to provide care for patients seeking treatment for pharyngitis. The number of patients without a primary care provider and seen at the pharmacy outside of normal office hours highlights the improved access that community pharmacyebased care offers.",
author = "Klepser, {Donald G.} and Klepser, {Michael E.} and Dering-Anderson, {Allison M.} and Morse, {Jacqueline A.} and Smith, {Jaclyn K.} and Klepser, {Stephanie A.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.japh.2015.11.013",
language = "English (US)",
volume = "56",
pages = "323--329.e1",
journal = "Journal of the American Pharmacists Association : JAPhA",
issn = "1544-3191",
publisher = "American Pharmacists Association",
number = "3",

}

TY - JOUR

T1 - Community pharmacistephysician collaborative streptococcal pharyngitis management program

AU - Klepser, Donald G.

AU - Klepser, Michael E.

AU - Dering-Anderson, Allison M.

AU - Morse, Jacqueline A.

AU - Smith, Jaclyn K.

AU - Klepser, Stephanie A.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Objectives: To describe patient outcomes associated with a community pharmacyebased, collaborative physician-pharmacist group A Streptococcus (GAS) management program. Setting: Fifty-five chain and independent community pharmacies in Michigan, Minnesota, and Nebraska. Practice innovation: Pharmacists screened clinically stable adult patients who presented with signs and symptoms consistent with GAS pharyngitis from October 1, 2013, to August 1, 2014, by means of Centor criteria, and performed a physical assessment followed by a rapid antigen detection test (RADT) for eligible patients. Patients were treated according to a collaborative practice agreement (CPA) with a licensed prescriber or a physician consult site model. Pharmacists followed up with patients 24e48 hours after the encounter to assess patient status and possible need for further intervention. Evaluation: Number of patients screened, tested, and treated, and health care utilization. Results: Of 316 patients screened, 43 (13.6%) were excluded and referred for care. Of 273 patients (86.4%) eligible for testing, 48 (17.6%) had positive test results and 46 (16.8%) received amoxicillin or azithromycin per the CPA. Of those tested, 43.2% had no primary provider and 43.9% visited the pharmacy outside of traditional clinic office hours. Conclusion: Pharmacists demonstrated the ability and capacity to provide care for patients seeking treatment for pharyngitis. The number of patients without a primary care provider and seen at the pharmacy outside of normal office hours highlights the improved access that community pharmacyebased care offers.

AB - Objectives: To describe patient outcomes associated with a community pharmacyebased, collaborative physician-pharmacist group A Streptococcus (GAS) management program. Setting: Fifty-five chain and independent community pharmacies in Michigan, Minnesota, and Nebraska. Practice innovation: Pharmacists screened clinically stable adult patients who presented with signs and symptoms consistent with GAS pharyngitis from October 1, 2013, to August 1, 2014, by means of Centor criteria, and performed a physical assessment followed by a rapid antigen detection test (RADT) for eligible patients. Patients were treated according to a collaborative practice agreement (CPA) with a licensed prescriber or a physician consult site model. Pharmacists followed up with patients 24e48 hours after the encounter to assess patient status and possible need for further intervention. Evaluation: Number of patients screened, tested, and treated, and health care utilization. Results: Of 316 patients screened, 43 (13.6%) were excluded and referred for care. Of 273 patients (86.4%) eligible for testing, 48 (17.6%) had positive test results and 46 (16.8%) received amoxicillin or azithromycin per the CPA. Of those tested, 43.2% had no primary provider and 43.9% visited the pharmacy outside of traditional clinic office hours. Conclusion: Pharmacists demonstrated the ability and capacity to provide care for patients seeking treatment for pharyngitis. The number of patients without a primary care provider and seen at the pharmacy outside of normal office hours highlights the improved access that community pharmacyebased care offers.

UR - http://www.scopus.com/inward/record.url?scp=84969141655&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969141655&partnerID=8YFLogxK

U2 - 10.1016/j.japh.2015.11.013

DO - 10.1016/j.japh.2015.11.013

M3 - Article

C2 - 27067554

AN - SCOPUS:84969141655

VL - 56

SP - 323-329.e1

JO - Journal of the American Pharmacists Association : JAPhA

JF - Journal of the American Pharmacists Association : JAPhA

SN - 1544-3191

IS - 3

ER -